Your browser is no longer supported. Please, upgrade your browser.
Settings
TBIO Translate Bio, Inc. daily Stock Chart
TBIO [NASD]
Translate Bio, Inc.
Index- P/E- EPS (ttm)-2.17 Insider Own31.15% Shs Outstand46.86M Perf Week-10.44%
Market Cap433.92M Forward P/E- EPS next Y-1.94 Insider Trans- Shs Float31.17M Perf Month-1.07%
Income-98.00M PEG- EPS next Q-0.48 Inst Own59.70% Short Float6.79% Perf Quarter68.98%
Sales1.40M P/S309.95 EPS this Y-32.40% Inst Trans0.25% Short Ratio9.75 Perf Half Y61.32%
Book/sh2.74 P/B3.38 EPS next Y-10.90% ROA-41.50% Target Price21.50 Perf Year-
Cash/sh3.08 P/C3.01 EPS next 5Y- ROE- 52W Range4.81 - 16.60 Perf YTD23.47%
Dividend- P/FCF- EPS past 5Y- ROI-78.70% 52W High-44.22% Beta-
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low92.52% ATR1.01
Employees81 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)37.96 Volatility8.54% 11.05%
OptionableNo Debt/Eq0.00 EPS Q/Q73.50% Profit Margin- Rel Volume2.48 Prev Close9.40
ShortableYes LT Debt/Eq0.00 EarningsMar 21 Payout- Avg Volume216.94K Price9.26
Recom1.50 SMA20-17.60% SMA50-5.64% SMA2002.56% Volume519,875 Change-1.49%
Dec-24-18Initiated H.C. Wainwright Buy $21
Jul-23-18Initiated Leerink Partners Outperform $24
Jul-23-18Initiated Evercore ISI Outperform $25
Jul-23-18Initiated Citigroup Buy $20
Apr-11-19 07:30AM  Translate Bio Appoints Robert Plenge, M.D., Ph.D., to its Board of Directors GlobeNewswire
Apr-08-19 04:05PM  Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting GlobeNewswire
07:30AM  Translate Bio Appoints Richard Wooster as Chief Scientific Officer GlobeNewswire
Apr-01-19 07:30AM  Translate Bio Appoints Pasquale (Pat) Sacco as Senior Vice President of Technical Operations GlobeNewswire +25.32%
Mar-26-19 07:30AM  Translate Bio Granted U.S. Patent Relating to Messenger RNA (mRNA) Delivery GlobeNewswire
Mar-25-19 07:30AM  Translate Bio to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-21-19 04:29PM  Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights GlobeNewswire
Mar-18-19 07:30AM  Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy GlobeNewswire +15.78%
Mar-04-19 07:30AM  Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference GlobeNewswire -9.87%
Feb-27-19 04:30PM  Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs GlobeNewswire
Feb-14-19 07:30AM  Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference GlobeNewswire
Jan-24-19 02:30PM  Moderna's Hot New mRNA Technology Has Competition Motley Fool
Jan-22-19 07:30AM  Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire -11.39%
Jan-04-19 03:26PM  [$$] Translate Bio Shares Surge The Wall Street Journal +23.60%
Jan-03-19 07:30AM  Translate Bio Appoints Robert Meyer, MD, to its Board of Directors GlobeNewswire -9.48%
07:30AM  Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency GlobeNewswire
Dec-23-18 02:37AM  Should You Avoid Translate Bio, Inc. (TBIO)? Insider Monkey
Dec-20-18 01:08PM  DAFNA Capital Management Return, AUM and Holdings Insider Monkey -6.59%
Dec-07-18 06:11PM  [$$] Moderna IPO Marks Milestone for New Biotech Market The Wall Street Journal
Dec-04-18 09:15AM  Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT) GlobeNewswire +5.94%
Nov-23-18 10:10AM  Do Institutions Own Shares In Translate Bio Inc (NASDAQ:TBIO)? Simply Wall St.
Nov-08-18 04:21PM  Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights GlobeNewswire
Nov-01-18 07:30AM  Translate Bio to Participate in Upcoming Investor Conferences GlobeNewswire
Oct-18-18 07:30AM  Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference GlobeNewswire
Sep-25-18 07:30AM  Translate Bio to Participate in the Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Aug-30-18 07:30AM  Translate Bio to Participate in Citis 13th Annual Biotech Conference GlobeNewswire
Aug-09-18 04:17PM  Translate Bio Announces Second Quarter 2018 Financial Results and Highlights Recent Development and Corporate Achievements GlobeNewswire
Jul-23-18 04:48PM  Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B Benzinga
11:00AM  Translate Bio's Novel mRNA Therapy Candidate Addresses A Key Investor Concern, Citi Says Benzinga
Jul-09-18 07:00AM  Translate Bio Announces Closing of Collaboration and Licensing Agreement with Sanofi Pasteur to Develop mRNA Vaccines for Infectious Diseases GlobeNewswire
Jul-02-18 07:30AM  [$$] Biotech Companies Continue IPO Hot Streak, But For How Long? The Wall Street Journal
Jun-27-18 07:26PM  Translate Bio Announces Pricing of Initial Public Offering Business Wire
Jun-24-18 11:02AM  The IPO Outlook For The Week: Shipping, Medtech, Mobility And Retail Benzinga
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.